MT Pharma America, Inc.
525 Washington Boulevard
About MT Pharma America, Inc.Based in Jersey City, New Jersey, MT Pharma America is a wholly-owned subsidiary of MTPC's 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MT Pharma America is dedicated to delivering innovative solutions that address the unmet medical needs of patients in the United States. It was established by MTPC to commercialize approved pharmaceutical products in the U.S. with plans to expand its product line through collaborations with partners.
President: Atsushi Fujimoto
CCO: Tom Larson
Please click here for MT Pharma America job opportunities.
8 articles with MT Pharma America, Inc.
Privately-held ITF Pharma snagged regulatory approval for Tiglutik, a liquid formulation of riluzole for the treatment of amyotrophic lateral sclerosis.
ALS is a progressive neurodegenerative disease that affects neurons in the brain and the spinal cord. The disease is usually fatal within two to five years of diagnosis. While there is no cure for the disease, multiple companies are working on treatments hoping to be the first to provide a viable...
With a Strong Focus on ALS Patients, Mitsubishi Tanabe Pharma America Works to Increase Access an...
5/31/2018It has been one year since Mitsubishi Tanabe Pharma America’s Radicava was approved as the first treatment for amyotrophic lateral sclerosis (ALS) in more than 20 years. Since its approval, MTPA has been aggressive in its efforts to get the medication in the hands of ALS patients.
MT Pharma America Begins Patient Insurance Benefits Investigation Process In Advance Of Availability Of RADICAVA (Edaravone)
MT Pharma America Enrolls More Than 700 Sites Of Care In Newly Created National Infusion Center Directory For ALS Patients
MT Pharma America Presents 12-Month RADICAVA (Edaravone) And Amyotrophic Lateral Sclerosis Data At The European Network For The Cure Of ALS (ENCALS) Annual Meeting